|
Table 1: Characteristics of the studied population in relation to the presence of BSI. |
||||
|
Variables |
Bacteremiaa N = 55 n (%) |
No bacteremia N = 260 n (%) |
Total |
p (< 0.05) |
|
Gender |
||||
|
Female |
28 (50.91) |
129 (49.62) |
157 |
0.86 |
|
Male |
27 (49.09) |
131 (50.38) |
158 |
|
|
Age (years)b |
6 (2-10) |
6 (3-9) |
315 |
0.98 |
|
Cancer type |
||||
|
ALL |
38 (69.09) |
150 (57.69) |
188 |
0.12 |
|
AML |
9 (16.36) |
48 (18.46) |
57 |
0.71 |
|
Lymphomas |
2 (3.64) |
24 (9.23) |
26 |
0.28 |
|
Solid tumors |
4 (7.27) |
29 (11.15) |
33 |
0.48 |
|
Other |
2 (3.64) |
9 (3.46) |
11 |
1.00 |
|
Days between chemotherapy and feverb |
7 (12.73) |
10 (5-14) |
270 |
0.02 |
|
Temperatureb |
38.5 (38.2-39.0) |
38.5 (38.1-38.8) |
315 |
0.13 |
|
Use of implantofix |
30 (54.54) |
112 (43.08) |
142 |
0.12 |
|
Comorbiditiesc |
26 (47.27) |
72 (27.69) |
98 |
0.01 |
|
Previous ABd |
30 (54.54) |
133 (51.15) |
163 |
0.89 |
|
AB prophylaxise |
31 (56.36) |
169 (65.00) |
200 |
0.23 |
|
ANC at startf |
40 (4-200) |
85 (20-286) |
315 |
0.49 |
|
Days of severe neutropeniab |
10 (5-15) |
6 (4-9) |
302 |
< 0.01 |
|
CRP at the beginning of the episodeb |
192 (96-192) |
48 (24-96) |
304 |
< 0.01 |
|
Clinical infectious focus |
||||
|
ORL |
3 (5.45) |
29 (11.15) |
32 |
0.32 |
|
Respiratory |
17 (30.90) |
81 (31.15) |
98 |
0.97 |
|
Gastrointestinal |
20 (36.36) |
55 (21.15) |
75 |
0.02 |
|
Skin |
10 (18.18) |
20 (7.69) |
30 |
0.02 |
|
Unknown |
16 (29.09) |
103 (39.62) |
119 |
0.14 |
|
Microbial isolation |
55 (100.00) |
52 (20.00) |
107 |
< 0.01 |
|
GPC |
12 (21.82) |
11 (4.23) |
23 |
< 0.01 |
|
GNB |
44 (80.00) |
39 (15.00) |
83 |
< 0.01 |
|
Fungus |
6 (10.91) |
3 (1.15) |
9 |
< 0.01 |
|
Unusual resistancese |
15 (27.27) |
6 (2.31) |
21 |
< 0.01 |
|
BSI = bloodstream infections; CI = confidence interval; ALL = acute lymphoid leukemia; AML = acute myeloid leukemia; AB = antibiotic; ANC = absolute neutrophil count; CRP = C-reactive protein; ORL = otorhinolaryngological; GPC = Gram-positive cocci; GNB = Gram-negative Bacilli. a CDC = Center for Disease Control and Prevention, criteria 2018 (Annex 1). b Median interquartile range (IQR). c Comorbidities: down syndrome, other chromosomopathies, congenital heart disease, chronic pneumopathy, malnutrition, hypothyroidism, epilepsy, psychomotor delay, renal insufficiency, others. d Last three months. e Trimetroprim sulfamethoxazole. f GNB producers of extended spectrum Beta-lactamase (ESBL), with a suggestive pattern of carbapenemase production, a suggestive pattern of multi-drug resistance, Gram positive vancomycin resistant cocci. |
||||